Literature DB >> 8827585

Bayesian individualization via sampling-based methods.

J Wakefield1.   

Abstract

We consider the situation where we wish to adjust the dosage regimen of a patient based on (in general) sparse concentration measurements taken on-line. A Bayesian decision theory approach is taken which requires the specification of an appropriate prior distribution and loss function. A simple method for obtaining samples from the posterior distribution of the pharmacokinetic parameters of the patient is described. In general, these samples are used to obtain a Monte Carlo estimate of the expected loss which is then minimized with respect to the dosage regimen. Some special cases which yield analytic solutions are described. When the prior distribution is based on a population analysis then a method of accounting for the uncertainty in the population parameters is described. Two simulation studies showing how the methods work in practice are presented.

Entities:  

Mesh:

Year:  1996        PMID: 8827585     DOI: 10.1007/bf02353512

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  9 in total

1.  Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.

Authors:  M Davidian; A R Gallant
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

3.  Implementation and evaluation of control strategies for individualizing dosage regimens, with application to the aminoglycoside antibiotics.

Authors:  D Katz; D Z D'Argenio
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

4.  Modelling of individual pharmacokinetics for computer-aided drug dosage.

Authors:  L B Sheiner; B Rosenberg; K L Melmon
Journal:  Comput Biomed Res       Date:  1972-10

5.  A priori lithium dosage regimen using population characteristics of pharmacokinetic parameters.

Authors:  J Gaillot; J L Steimer; A J Mallet; J J Thebault; A Bieder
Journal:  J Pharmacokinet Biopharm       Date:  1979-12

Review 6.  An efficient control strategy for dosage regimens.

Authors:  C Hu; W S Lovejoy; S L Shafer
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

7.  OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.

Authors:  A W Kelman; B Whiting; S M Bryson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

8.  Methods for evaluating optimal dosage regimens and their application to theophylline.

Authors:  O Richter; D Reinhardt
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1982-12

9.  Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharm Sci       Date:  1982-12       Impact factor: 3.534

  9 in total
  11 in total

1.  A comparison of a Bayesian population method with two methods as implemented in commercially available software.

Authors:  J E Bennett; J C Wakefield
Journal:  J Pharmacokinet Biopharm       Date:  1996-08

2.  Bayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development.

Authors:  Joo Yeon Lee; Jogarao V S Gobburu
Journal:  AAPS J       Date:  2011-07-27       Impact factor: 4.009

3.  Modeling of trough plasma bismuth concentrations.

Authors:  J E Bennett; J C Wakefield; L F Lacey
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

Review 4.  Use of pathway information in molecular epidemiology.

Authors:  Duncan C Thomas; David V Conti; James Baurley; Frederik Nijhout; Michael Reed; Cornelia M Ulrich
Journal:  Hum Genomics       Date:  2009-10       Impact factor: 4.639

5.  Implementation and evaluation of a stochastic control strategy for individualizing teicoplanin dosage regimen.

Authors:  M Tod; P Alet; O Lortholary; O Petitjean
Journal:  J Pharmacokinet Biopharm       Date:  1997-12

6.  A new probabilistic rule for drug-dug interaction prediction.

Authors:  Jihao Zhou; Zhaohui Qin; Sara K Quinney; Seongho Kim; Zhiping Wang; Menggang Yu; Jenny Y Chien; Aroonrut Lucksiri; Stephen D Hall; Lang Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-01-21       Impact factor: 2.745

7.  A continued learning approach for model-informed precision dosing: Updating models in clinical practice.

Authors:  Corinna Maier; Jana de Wiljes; Niklas Hartung; Charlotte Kloft; Wilhelm Huisinga
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-12-27

8.  Bayesian inference for generalized linear mixed model based on the multivariate t distribution in population pharmacokinetic study.

Authors:  Fang-Rong Yan; Yuan Huang; Jun-Lin Liu; Tao Lu; Jin-Guan Lin
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

9.  Addressing human variability in next-generation human health risk assessments of environmental chemicals.

Authors:  Lauren Zeise; Frederic Y Bois; Weihsueh A Chiu; Dale Hattis; Ivan Rusyn; Kathryn Z Guyton
Journal:  Environ Health Perspect       Date:  2012-10-19       Impact factor: 9.031

10.  Bayesian Data Assimilation to Support Informed Decision Making in Individualized Chemotherapy.

Authors:  Corinna Maier; Niklas Hartung; Jana de Wiljes; Charlotte Kloft; Wilhelm Huisinga
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.